JP2021512150A5 - - Google Patents
Info
- Publication number
- JP2021512150A5 JP2021512150A5 JP2020561587A JP2020561587A JP2021512150A5 JP 2021512150 A5 JP2021512150 A5 JP 2021512150A5 JP 2020561587 A JP2020561587 A JP 2020561587A JP 2020561587 A JP2020561587 A JP 2020561587A JP 2021512150 A5 JP2021512150 A5 JP 2021512150A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- compound
- pharmaceutical composition
- alkyl
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620842P | 2018-01-23 | 2018-01-23 | |
| US62/620,842 | 2018-01-23 | ||
| PCT/US2019/014738 WO2019147662A1 (en) | 2018-01-23 | 2019-01-23 | 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512150A JP2021512150A (ja) | 2021-05-13 |
| JPWO2019147662A5 JPWO2019147662A5 (https=) | 2022-02-24 |
| JP2021512150A5 true JP2021512150A5 (https=) | 2022-02-24 |
| JP7214752B2 JP7214752B2 (ja) | 2023-01-30 |
Family
ID=65352181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561587A Active JP7214752B2 (ja) | 2018-01-23 | 2019-01-23 | 免疫調節剤として有用な２，８－ジアシル－２，８－ジアザスピロ［５．５］ウンデカン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11414418B2 (https=) |
| EP (1) | EP3743425B1 (https=) |
| JP (1) | JP7214752B2 (https=) |
| KR (1) | KR102738303B1 (https=) |
| CN (1) | CN111868061A (https=) |
| ES (1) | ES2998139T3 (https=) |
| WO (1) | WO2019147662A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018005374A1 (en) | 2016-06-27 | 2018-01-04 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR20190133714A (ko) | 2017-03-27 | 2019-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 치환된 이소퀴놀린 유도체 |
| AU2018306619B2 (en) | 2017-07-28 | 2022-06-02 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN111225665B (zh) | 2017-08-08 | 2023-12-08 | 凯莫森特里克斯股份有限公司 | 大环免疫调节剂 |
| JP7387616B2 (ja) | 2018-02-22 | 2023-11-28 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン |
| EP3759093B1 (en) | 2018-03-01 | 2022-11-30 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| CN113891748A (zh) | 2019-03-28 | 2022-01-04 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| AU2020276277B2 (en) | 2019-05-15 | 2025-03-20 | Chemocentryx, Inc. | Triaryl compounds for treatment of PD-L1 diseases |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| SG11202112875UA (en) | 2019-06-20 | 2021-12-30 | Chemocentryx Inc | Compounds for treatment of pd-l1 diseases |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| CA3153777A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| AU2020368393B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| CN114555080B (zh) | 2019-10-16 | 2025-10-10 | 凯莫森特里克斯股份有限公司 | 用于治疗pd-l1疾病的杂芳基联苯胺 |
| BR112022008191A2 (pt) | 2019-11-08 | 2022-07-12 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para melanoma |
| BR112023003427A2 (pt) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para carcinoma hepatocelular |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022087402A1 (en) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| KR20240099362A (ko) | 2021-10-29 | 2024-06-28 | 브리스톨-마이어스 스큅 컴퍼니 | 혈액암에 대한 lag-3 길항제 요법 |
| CA3249004A1 (en) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Polytherapy for Hepatocellular Carcinoma |
| US20230326022A1 (en) | 2022-04-08 | 2023-10-12 | Bristol-Myers Squibb Company | Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures |
| CN120731228A (zh) | 2022-12-21 | 2025-09-30 | 百时美施贵宝公司 | 肺癌的组合疗法 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| IN2014DN09346A (https=) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| JP6417419B2 (ja) | 2013-09-04 | 2018-11-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 免疫調節剤として有用な化合物 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN109689640B (zh) | 2016-07-08 | 2022-01-04 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP7106572B2 (ja) | 2016-12-20 | 2022-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な化合物 |
| KR20190133714A (ko) | 2017-03-27 | 2019-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 치환된 이소퀴놀린 유도체 |
| EP3759093B1 (en) | 2018-03-01 | 2022-11-30 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
-
2019
- 2019-01-23 JP JP2020561587A patent/JP7214752B2/ja active Active
- 2019-01-23 EP EP19704161.9A patent/EP3743425B1/en active Active
- 2019-01-23 WO PCT/US2019/014738 patent/WO2019147662A1/en not_active Ceased
- 2019-01-23 US US16/963,557 patent/US11414418B2/en active Active
- 2019-01-23 KR KR1020207023902A patent/KR102738303B1/ko active Active
- 2019-01-23 ES ES19704161T patent/ES2998139T3/es active Active
- 2019-01-23 CN CN201980019795.1A patent/CN111868061A/zh active Pending